Agenda Item 9

1. Comments on the principles and procedure for the parallel review of a new veterinary drug by JECFA and national regulatory agencies (CL 2021/5/OCS-RVDF)

   a. General Comments: Kenya supports the parallel review of a new veterinary drug as an alternative / complement to the current process to assess new compounds by JECFA for the establishment of Codex MRLs by CCRVDF. The overall format and content of the proposed procedure is agreeable.

   b. Specific comments:

      (i) Principles: Kenya has no additional proposals to the principles and the text.

      (ii) Procedure: Kenya takes note of the phases outlined in the procedures and would wish to provide the following comments:

         Phase 1: Identification of a candidate: Kenya proposes amendment to the text by deleting the word ‘...some or all of...’ in the last sentence of paragraph 1 to read...... A proposed veterinary drug shall meet the following criteria:

         Phase 2 Submission: Kenya proposes amendment to the text to read as follows .... A product is submitted (or is expected to be submitted) to a national regulatory authority, most likely in one of the larger markets (in practice, most veterinary products are first submitted for review in the U.S. or in Europe). At the following CCRVDF meeting, the product would be submitted (by the Codex Member who received the product application or is expected to receive the application by a certain date) for inclusion on the priority list at CCRVDF (Step 1).

Agenda Item 10

2. Comments on the recommendations for the further steps on the use and maintenance of the database on countries’ needs for maximum residue limits for veterinary drugs in foods (CL 2021/2/OCS-RVDF)

General Comments: Kenya supports these recommendations it provides the much needed flexibility for member countries to submit their needs for MRLs.